EN DE
Watch Cereno Scientific AB Series B for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cereno Scientific AB Series B (CRNO-B) fair value: what the stock is really worth

As of Nov 3, 2026: fair value (intrinsic value) of Cereno Scientific AB Series B stock SEK 1.28, price SEK 1.63, that is 21.6% below the price, quality 32 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE

CS Cereno Scientific AB Series B logo Thin data Nov 11, 2026

Cereno Scientific AB Series B

CRNO-B · ST
Expensive, weak quality

Our calculation puts a fair price 22% below what the stock costs today.

Low debt
Fair value kr 1.28 · Overvalued
Quality 32/100
Loss-making · -163.2% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 3/100 · thin data
Thin data
Estimate
Watch Cereno Scientific AB Series B for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 11.74 kr 0.4610 Fair Value kr 1.28 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range kr 0.4610 – kr 11.74 · fair‑value band kr 0.9600 – kr 1.60 · the kr 1.63 price screens above the kr 1.28 fair value. As of Nov 11, 2026.

Follow Cereno Scientific AB Series B in your weekly email

Every Wednesday you see whether Cereno Scientific AB Series B is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden.

Show moreShow less

The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms.

Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I clinical trial for the treatment of cardiovascular, pulmonary diseases, pulmonary hypertension, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases.

The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System.

Cereno Scientific AB (publ) was incorporated in 2012 and is headquartered in Gothenburg, Sweden.

Stock analysis

Cereno Scientific AB Series B (CRNO-B) currently trades at kr 1.63, while our estimate is kr 1.28, 22% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.9600 (bear) to kr 1.60 (bull), the price of kr 1.63 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Cereno Scientific AB Series B reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2021. Reported net income was −118M SEK in FY2025.

Key figures

Market cap 510M SEK (≈ $51.7M) Micro · P/S ratio 6.57 · EPS (TTM) kr −0.4100 · Return on equity −61.9% · Return on assets (EBIT) −14.5% (5-year average) · Operating margin −74.4% · Revenue (TTM) 80.5M SEK · Revenue growth (YoY) +421%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 81% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −22%, CRNO-B screens cheaper than that median.

Fair Value

Bear kr 0.9600 Fair Value kr 1.28 Bull kr 1.60
Price kr 1.63 · Downside -21.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 31
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 38
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CRNO-B screens overvalued: fair value 22% below the price. Compare with Merck KGaA →

Compare Cereno Scientific AB Series B with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −21.6% · Below median
Profitability
Return on assets −29.2% · Bottom 25%
Net margin (12 months) −163.2% · Bottom 25%
Operating margin (12 months) −74.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 420.5% · Top 25%
Balance sheet
Debt / equity 0.50× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.02× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 6.33× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)5 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)75 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs CRNO-B
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs CRNO-B
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs CRNO-B
Haleon plc HLN $9.06 $8.62 −5% vs CRNO-B
Merck KGaA MRK €149.35 €109.18 −27% vs CRNO-B
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs CRNO-B
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs CRNO-B
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs CRNO-B
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs CRNO-B
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs CRNO-B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cereno Scientific AB Series B: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cereno Scientific AB Series B Fair Value". https://www.fairvalue-calculator.com/stock/CRNO-B

Frequently asked questions

Is Cereno Scientific AB Series B (CRNO-B) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is kr 1.28 versus the last price from Nov 3, 2026 of kr 1.63, about 22% lower (overvalued).
What is the fair value of CRNO-B?
Our estimate for Cereno Scientific AB Series B is kr 1.28 (as of Nov 11, 2026), built from audited fundamentals. Last price (from Nov 3, 2026): kr 1.63.
What is the quality score of CRNO-B?
Cereno Scientific AB Series B has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cereno Scientific AB Series B (CRNO-B)?
Our calculated price target is the estimate of kr 1.28 (as of Nov 11, 2026). Cautious scenario kr 0.9600, optimistic scenario kr 1.60. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cereno Scientific AB Series B stock forecast for 2026?
Our estimate puts fair value at kr 1.28, about 22% lower versus the last price from Nov 3, 2026 of kr 1.63 (overvalued). Cautious scenario kr 0.9600, optimistic scenario kr 1.60. The calculation is refreshed regularly with new filings.
What is the revenue of Cereno Scientific AB Series B (CRNO-B)?
Cereno Scientific AB Series B reported trailing-twelve-month revenue of about 80.5M SEK (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Cereno Scientific AB Series B (CRNO-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cereno Scientific AB Series B it is kr 1.28 per share (as of Nov 11, 2026), against a price of kr 1.63.
Is Cereno Scientific AB Series B stock overvalued or undervalued in 2026?
As of Nov 11, 2026, CRNO-B trades above its calculated fair value: price kr 1.63, fair value kr 1.28, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRNO-B?
No. The price is what the market pays today (kr 1.63); the fair value is what the company's own numbers justify (kr 1.28). For Cereno Scientific AB Series B the two are kr 0.3530 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cereno Scientific AB Series B worth?
The market values Cereno Scientific AB Series B at about 510M SEK (market capitalisation, as of Nov 11, 2026). Per share that is kr 1.63; our models calculate a fair value of kr 1.28 per share.
What do the bullish and bearish scenarios say about CRNO-B?
Our models span a range for Cereno Scientific AB Series B: cautious scenario kr 0.9600, base kr 1.28, optimistic kr 1.60 per share (as of Nov 11, 2026, price kr 1.63). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cereno Scientific AB Series B (CRNO-B)?
Balance-sheet figures for Cereno Scientific AB Series B (as of Nov 11, 2026): return on equity −61.9%, debt of 0.50 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is CRNO-B from its 52-week high?
Cereno Scientific AB Series B trades at kr 1.63, about 81% below its 52-week high of kr 8.55 and at the low of kr 1.63 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 1.28 is for.
Which stocks are comparable to Cereno Scientific AB Series B?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cereno Scientific AB Series B stock attractive at the current price?
The data as of Nov 11, 2026: price kr 1.63, calculated fair value kr 1.28 (−22%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Cereno Scientific AB Series B itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cereno Scientific AB Series B (CRNO-B)?
The latest price we hold is from Nov 3, 2026 and stands at kr 1.63. Our estimate is kr 1.28, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cereno Scientific AB Series B right now?
The price sits above even our optimistic bull case (kr 1.60). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Cereno Scientific AB Series B

How large is the market capitalisation of Cereno Scientific AB Series B (CRNO-B)?
The market capitalisation of Cereno Scientific AB Series B is 510M SEK (≈ $51.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cereno Scientific AB Series B (CRNO-B)?
The price-to-sales ratio of Cereno Scientific AB Series B is 6.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cereno Scientific AB Series B (CRNO-B)?
Earnings per share at Cereno Scientific AB Series B are kr −0.4100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cereno Scientific AB Series B (CRNO-B)?
The return on equity (ROE) of Cereno Scientific AB Series B is −61.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cereno Scientific AB Series B (CRNO-B)?
On an EBIT basis the return on assets of Cereno Scientific AB Series B is −14.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cereno Scientific AB Series B (CRNO-B)?
The operating margin of Cereno Scientific AB Series B is −74.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cereno Scientific AB Series B (CRNO-B)?
Revenue at Cereno Scientific AB Series B is growing +421% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cereno Scientific AB Series B (CRNO-B) generate?
The free cash flow of Cereno Scientific AB Series B is −156M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cereno Scientific AB Series B (CRNO-B) carry?
The net debt of Cereno Scientific AB Series B is 50.4M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cereno Scientific AB Series B in the live analysis

One click puts Cereno Scientific AB Series B on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.